Arno Therapeutics Doses First Patient in Expansion Stage of Modified Phase I/II Trial Evaluating Onapristone in Progesterone Receptor Positive Tumors
December 10, 2014 09:00 ET
|
Arno Therapeutics Inc.
FLEMINGTON, N.J., Dec. 10, 2014 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company primarily focused on the development of oncology therapeutics,...
Arno Therapeutics to Present Data Further Validating Diagnostic Development of CDx for Onapristone at San Antonio Breast Cancer Symposium 2014
December 09, 2014 09:00 ET
|
Arno Therapeutics Inc.
Abstract #5567
Poster #P5-02-13
Poster Session 5
Friday, December 12; 5:00 – 7:00 p.m. CT
Track: Diagnostic Pathology,...
Arno Therapeutics Appoints Alexander Zukiwski, M.D. to Board of Directors
December 04, 2014 08:30 ET
|
Arno Therapeutics Inc.
FLEMINGTON, N.J., Dec. 4, 2014 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused primarily on the development of oncology therapeutics, today...
Arno Therapeutics to Present at LD Micro Conference 2014
November 24, 2014 08:30 ET
|
Arno Therapeutics Inc.
FLEMINGTON, N.J., Nov. 24, 2014 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today...
Arno Therapeutics Reports Third Quarter 2014 Financial and Business Update
November 14, 2014 16:34 ET
|
Arno Therapeutics Inc.
FLEMINGTON, N.J., Nov. 14, 2014 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today...
Arno Therapeutics' Executive Selected to Present at 5th Annual Clinical Affairs and Regulatory Approvals for Diagnostics Conference
October 29, 2014 08:30 ET
|
Arno Therapeutics Inc.
FLEMINGTON, N.J., Oct. 29, 2014 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today...
Arno Therapeutics Advances Phase I Trial Evaluating Onapristone in Progesterone Receptor Positive Tumors to Expansion Stage
October 27, 2014 08:30 ET
|
Arno Therapeutics Inc.
FLEMINGTON, N.J., Oct. 27, 2014 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today...
Arno Therapeutics to Present Encouraging Data From Ongoing Phase I/II Trial Evaluating Onapristone in CRPC at 21st Annual PCF Scientific Retreat
October 23, 2014 08:30 ET
|
Arno Therapeutics Inc.
FLEMINGTON, N.J., Oct. 23, 2014 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today...
Arno Therapeutics to Present at the 13th Annual BIO Investor Forum
September 30, 2014 08:30 ET
|
Arno Therapeutics Inc.
FLEMINGTON, N.J., Sept. 30, 2014 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today...
Arno Therapeutics' Executive Selected to Chair World CDx Boston 2014
September 18, 2014 08:30 ET
|
Arno Therapeutics Inc.
FLEMINGTON, N.J., Sept. 18, 2014 (GLOBE NEWSWIRE) -- Arno Therapeutics, Inc. (OTCQB:ARNI), a clinical stage biopharmaceutical company focused on the development of oncology therapeutics, today...